Add this topic to your myFT Digest for news straight to your inbox
Chief executive of aspirin-to-Roundup group has limited options to sort fallout of ill-fated Monsanto purchase
The company’s deleveraging route looks long and distinctly uncertain
Bill Anderson quashes speculation after suspending break-up of indebted German drugs-to-pesticides group
Plus, Bayer resists break-up calls and Warren Buffett sours on one of Berkshire’s biggest business units
Bill Anderson expects further profit declines at the aspirin-to-agriculture conglomerate in 2024
Company is pushing for legislation that would limit its legal exposure over allegedly carcinogenic product
Senior minister Benny Gantz’s White House visit lays bare growing tensions within Israel’s war cabinet
Struggling German chemicals group announces boardroom reshuffle ahead of update on potential break-up
Spinning off consumer health is no easy fix but a sale would offer a quicker turnaround
German conglomerate is still struggling with the costly fallout of its $63bn acquisition of Monsanto
Bill Anderson says group is generating a series of promising new drugs after R&D strategy change
Halted trial of prospective blockbuster treatment follows latest US legal blow over weedkiller Roundup
German group says prospective blockbuster asundexian failed to demonstrate efficacy
German group is examining spinning off its crop sciences or consumer health businesses in effort to restore fortunes
There is a case for a break-up at the German conglomerate
Also in today’s newsletter, ‘Burning Man for climate geeks’
German group has paid out and provisioned billions of dollars but has yet to put litigation fully behind it
New chief needs to signal to investors whether a restructuring is likely
Two companies Viessmann and Bayer opt for starkly different approaches when confronted with a strategic challenge
Bill Anderson intends to empower and involve staff in decision making at the 159-year-old German conglomerate
The need to untangle differences in business culture, politics and regulation means the region’s legal sector is open up to experimentation
Bluebell Capital Partners calls for conglomerate’s break-up and boardroom reshuffle ahead of AGM
Conglomerate faces ‘unique challenges’ but separating pharma and agrichemical units not a done deal
Companies are ‘at the mercy of an industry of litigation lawyers’, says outgoing CEO Werner Baumann
But high-profile shareholder may not be satisfied with informal position
International Edition